← Back to Analyst Consensus 
AMLX Buy
Amylyx Pharmaceuticals, Inc.
Current Price —
Implied Upside —
Analysts 18
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 1 reiterations from 1 firms
Next Earnings
Nov 5, 2026 (10 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 15, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| Aug 27, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Aug 19, 2026 | Mizuho | maintain | Outperform → Outperform | — | 52% |
| Aug 19, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Aug 19, 2026 | Baird | maintain | Outperform → Outperform | — | 55% |
| Aug 18, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Aug 17, 2026 | Mizuho | maintain | Outperform → Outperform | — | 52% |
| Aug 3, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| Jul 20, 2026 | Mizuho | maintain | Outperform → Outperform | — | 52% |
| Jun 25, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Apr 28, 2026 | Mizuho | maintain | Outperform → Outperform | — | 52% |
| Mar 25, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Mar 19, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Mar 4, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Mar 3, 2026 | Stifel | initiate | — → Buy | — | 53% |
| Feb 20, 2026 | B of A Securities | maintain | Buy → Buy | $19 | 53% |
| Feb 10, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | $28 | 44% |
| Nov 7, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $20 | 44% |
| Oct 17, 2025 | Citigroup | maintain | Buy → Buy | $20 | 54% |
| Oct 16, 2025 | Baird | maintain | Outperform → Outperform | $19 | 55% |
| Oct 3, 2025 | B of A Securities | maintain | Buy → Buy | $16 | 53% |
| Sep 16, 2025 | Goldman Sachs | maintain | Buy → Buy | $20 | 54% |
| Sep 15, 2025 | Guggenheim | maintain | Buy → Buy | $25 | 52% |
| Aug 28, 2025 | B of A Securities | maintain | Buy → Buy | $14 | 53% |
| Jun 24, 2025 | Guggenheim | initiate | — → Buy | $17 | 52% |
| Jun 17, 2025 | Citigroup | initiate | — → Buy | $12 | 54% |
| May 14, 2025 | Mizuho | maintain | Outperform → Outperform | $8 | 52% |
| May 9, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $16 | 44% |
| May 7, 2025 | Leerink Partners | upgrade | Market Perform → Outperform | $10 | 51% |
| Apr 7, 2025 | Mizuho | upgrade | Neutral → Outperform | $7 | 52% |
| Mar 5, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $12 | 44% |
| Dec 5, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $12 | 44% |
| Nov 18, 2024 | Baird | upgrade | Neutral → Outperform | $11 | 55% |
| Nov 8, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $12 | 44% |
| Oct 18, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $8 | 44% |
| Jul 12, 2024 | Goldman Sachs | maintain | Neutral → Neutral | $4 | 54% |
| Jul 10, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $8 | 44% |
| Jun 24, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $8 | 44% |
| May 14, 2024 | Mizuho | maintain | Neutral → Neutral | $3 | 52% |
| May 10, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $8 | 44% |
| Apr 11, 2024 | Baird | maintain | Neutral → Neutral | $3 | 55% |
| Apr 11, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $8 | 44% |
| Apr 8, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $8 | 44% |
| Mar 12, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $8 | 44% |
| Mar 11, 2024 | Deutsche Bank | maintain | Buy → Buy | $8 | 57% |
| Mar 11, 2024 | Goldman Sachs | downgrade | Buy → Neutral | $4 | 54% |
| Mar 11, 2024 | Leerink Partners | downgrade | Outperform → Market Perform | $0 | 51% |
| Mar 11, 2024 | Baird | downgrade | Outperform → Neutral | $4 | 55% |
| Mar 8, 2024 | Evercore ISI Group | downgrade | Outperform → In-Line | $0 | 58% |
| Mar 8, 2024 | Mizuho | reiterate | Buy → Buy | $32 | 52% |
Price Target Trend
Apr 23, 2026 Latest: $43 Oct 24, 2026
EPS Estimates
+1q $-0.36
Lo: $-0.41 Hi: $-0.24
8 analysts +1y $-1.09
Lo: $-1.63 Hi: $0.70
8 analysts ▲3
0y $-1.48
Lo: $-1.60 Hi: $-1.26
8 analysts 0q $-0.37
Lo: $-0.42 Hi: $-0.31
8 analysts Cross-Platform Signals
No cross-platform signals in the last 90 days